Author: BillionToOne

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

August 18, 2026
BillionToOne’s Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study

June 29, 2026

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions